Product Information:

RESMIROM 60mg Tablets contain Resmetirom 60mg, a selective thyroid hormone receptor-β (THR-β) agonist approved for the treatment of non-alcoholic steatohepatitis (NASH), now classified under Metabolic Dysfunction-Associated Steatohepatitis (MASH), in adults with moderate to advanced liver fibrosis.

Resmetirom activates THR-β receptors primarily in the liver, promoting fat metabolism, reducing hepatic fat accumulation, and decreasing inflammation and fibrosis—without significantly stimulating cardiac or bone tissues (mediated by THR-α).

⚠️ Important Note:

Resmetirom (brand name Rezdiffra™) received FDA approval in March 2024 as the first drug specifically indicated for MASH/NASH with fibrosis. The 60mg strength is typically used during dose titration before escalating to the maintenance dose (100mg). Availability in Pakistan may be limited to specialty centers as of 2026.

Uses of (RESMIROM 60MG TABLETS):

1. Treatment of MASH/NASH with liver fibrosis (stages F2–F3)
2. Reduction of hepatic fat, ballooning, lobular inflammation, and fibrosis progression
3. Adjunct to lifestyle modifications (weight loss, diet, exercise) in patients with metabolic syndrome, obesity, or type 2 diabetes

Key Benefits of (RESMIROM 60MG TABLETS):

1. Liver-targeted action with minimal systemic thyroid effects
2. Improves liver histology and reduces risk of cirrhosis
3. Lowers LDL cholesterol and triglycerides
4. Oral once-daily dosing with structured titration for tolerability

How To Use (RESMIROM 60MG TABLETS):

1. Take once daily with food (to enhance absorption).
2. Swallow whole with water—do not crush or chew.
3. Dosing regimen:
4. Weeks 1–4: 60mg once daily (initial titration phase)
5. From Week 5 onward: Increase to 100mg once daily if tolerated
6. Do not double dose if a dose is missed.

When Not to Use (RESMIROM 60MG TABLETS):

Do not use if you have:

1. Hypersensitivity to resmetirom
2. Severe hepatic impairment (Child-Pugh C)
3. Uncontrolled hyperthyroidism
4. Pregnancy or breastfeeding (safety not established)

Side Effects of (RESMIROM 60MG TABLETS):

Common:

1. Diarrhea, nausea, abdominal discomfort
2. Mild increase in resting heart rate (<5 bpm)
3. Transient ALT/AST elevations

Rare/Serious:

1. Gallstone formation or biliary colic (due to increased cholesterol mobilization)
2. Myalgia or elevated creatine kinase (CK)
3. Thyroid axis suppression (rare; monitor TSH if symptomatic)
4. Discontinue and seek medical evaluation if persistent right upper quadrant pain, jaundice, or muscle weakness occurs.

Dosage: (RESMIROM 60MG TABLETS):

1. Titration dose: 60mg once daily for 4 weeks
2. Maintenance: Escalate to 100mg once daily thereafter
3. Elderly or renal impairment: No dose adjustment required
4. Hepatic impairment (Child-Pugh A/B): Use with caution; not studied in Child-Pugh C

Who It’s For (RESMIROM 60MG TABLETS):

Adults with confirmed MASH/NASH and liver fibrosis (F2–F3) who are initiating resmetirom therapy and require gradual dose escalation to improve tolerability.

Warnings & Precautions:

1. Confirm diagnosis via liver biopsy, FibroScan, or validated non-invasive tests (e.g., ELF, FIB-4)
2. Assess baseline gallbladder status—monitor for biliary symptoms
3. Check ALT, AST, CK, lipids, and TSH before and during treatment
4. Combine with weight loss (≥7–10%) and metabolic control for optimal outcomes

Drug Interactions:

1. Statins: Additive LDL-lowering effect (generally beneficial)
2. Strong CYP2C9 inducers (e.g., rifampin): May reduce resmetirom exposure
3. No clinically significant interactions with metformin, GLP-1 agonists, or antihypertensives
4. Always inform your hepatologist or physician about all medications.

Additional Information:

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Available by prescription only in Pakistan, likely through specialized gastroenterology or hepatology centers.